Grace Therapeutics GRCE Insider Ownership

Updated Oct 16, 2026

Over the past 12 months, Grace Therapeutics insiders bought $471,695 of stock on the open market (224.9K shares) and made no open-market sales.

• Grace Therapeutics' open-market purchases in the past 12 months came from 2 insiders; no insider sold.
• Among Grace Therapeutics' insiders, the largest open-market purchases in the past 12 months were by Opaleye Management Inc. (10% owner), totaling $257,695 (124.9K shares), most recently on October 12, 2026.
• Business Quant data shows Grace Therapeutics insiders holding 4.31Mn shares in total in their latest Form 4 filings.
• Grace Therapeutics insiders hold 121.36K shares directly (2.82% of their total) and 4.19Mn shares (97.18%) indirectly, through entities such as trusts and partnerships.
• Business Quant counts 3 insiders with holdings in Grace Therapeutics stock, among the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Grace Therapeutics' three largest insider shareholders, based on their latest Form 4 filings, are Opaleye Management Inc. (10% owner, 2.87Mn shares), Vimal Kavuru (Director and 10% owner, 1.31Mn shares) and Prashant Kohli (Chief Executive Officer, 121.36K shares).
• The holding of Opaleye Management Inc. makes up 66.71% of all shares held by Grace Therapeutics insiders.
• Institutions owned 24.00% of GRCE shares as of Q2 2026; insiders' latest Form 4 filings account for about 24.94%, leaving roughly 51.06% with other investors, including the public.
• In the past year, 9 insiders of Grace Therapeutics submitted 19 Form 4 filings reporting trades, awards or other transactions.
• The insider data for GRCE reflects Form 4 filings through October 13, 2026.